Pfizer is seeking participants for a Lyme disease vaccine study.

The company is looking for 6,000 people to be a part of a study.

Those who participate will either get three doses and a booster of the vaccine or a placebo.

VLA15 is the only Lyme disease vaccine candidate currently in clinical development.

If the trial produces positive results, Pfizer says it may seek approval from the FDA within the next few years.

The CDC says over 400,000 people need treatment for Lyme disease each year.